P2.03-004 Recurrent Response to Advanced NSCLC with Erlotinib Developing Central Nervous System Failure during Gefitinib or Icotinib Treatment
نویسندگان
چکیده
منابع مشابه
Use of erlotinib or gefitinib as initial therapy in advanced NSCLC.
Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR), such as erlotinib (Tarceva) and gefitinib (Iressa), have shown remarkable activity in a portion of patients with non-small-cell lung cancer (NSCLC). Based on a large randomized controlled trial showing a survival benefit compared with placebo, erlotinib gained US Food and Drug Administration approval for us...
متن کاملComparison of effectiveness and adverse effects of gefitinib, erlotinib and icotinib among patients with non-small cell lung cancer: A network meta-analysis
The present network meta-analysis aimed to compare the effectiveness and adverse effects of gefitinib, erlotinib and icotinib in the treatment of patients with non-small cell lung cancer (NSCLC). Two reviewers searched the Cochrane, PubMed, Embase, ScienceDirect, China National Knowledge Infrastructure, VIP Database for Chinese Technical Periodicals and Wanfang databases for relevant studies. S...
متن کاملComplete response to erlotinib treatment in brain metastases from recurrent NSCLC.
We report a case of a 55 year old Chinese female never smoker who presented with a 6 month history of cough in October 2002. In November 2002 she underwent a right middle lobectomy for adenocarcinoma. In June 2003 a CT scan showed recurrences in the mediastinum, pleura, and ribs. In January 2004 she completed six cycles of treatment with gemcitabine and carboplatin and the CT scan following tre...
متن کاملCancer Therapy: Clinical Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib
Purpose: Gefitinib and erlotinib can penetrate into the central nervous system (CNS) and elicit responses in patients with brain metastases (BM) from non–small cell lung cancer (NSCLC). However, there are incomplete data about their impact on the development and control of CNS metastases. Experimental Design: Patients with stage IIIB/IV NSCLC with somatic EGFRmutations initially treated with ge...
متن کاملDevelopment of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.
PURPOSE Gefitinib and erlotinib can penetrate into the central nervous system (CNS) and elicit responses in patients with brain metastases (BM) from non-small cell lung cancer (NSCLC). However, there are incomplete data about their impact on the development and control of CNS metastases. EXPERIMENTAL DESIGN Patients with stage IIIB/IV NSCLC with somatic EGFR mutations initially treated with g...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2017
ISSN: 1556-0864
DOI: 10.1016/j.jtho.2017.09.1255